Tuesday, October 15, 2019
Fiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)
  SocialTwist Tell-a-Friend  

BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ --  New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (≥10 years of diagnosis) not  optimally controlled on their current basal-bolus regimen, Fiasp ® (fast-acting insulin aspart) effectively reduced overall blood sugar levels (HbA1c), compared with conventional insulin aspart.1

Novo Nordisk Logo

"As type 2 diabetes progresses, people living with this condition might require a mealtime insulin to bring their post-meal blood sugar spikes down. Yet, some people might still struggle with blood sugar control even after the addition of a mealtime insulin," said Dr Wendy Lane, Mountain Diabetes and Endocrine Center, Asheville, North Carolina, USA, and study lead researcher. "With its ultra-fast profile of action, Fiasp ® may be a suitable alternative option for people with type 2 diabetes struggling to manage their post-meal spikes."

In addition to effective overall blood sugar management, people treated with Fiasp ® reported superior reductions in one-hour post-meal blood sugar increment, compared to those receiving conventional insulin aspart.1

"Research has shown that elevated blood sugar levels can lead to severe health implications, especially in those who have lived with type 2 diabetes for a long time,"  said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "These trial results confirm that Fiasp ® offers superior post-mealtime reductions, compared to conventional insulin aspart, which may help more people with type 2 diabetes to achieve their intended blood sugar levels."

Fiasp ® also demonstrated a statistically significantly lower rate of severe or blood sugar-confirmed hypoglycaemia (low blood sugar) than conventional insulin aspart. Other adverse event rates were similar between Fiasp ® and conventional insulin aspart.1

About the trial1

The onset 9 trial (1,091 people randomised) was a phase 3, multicentre, double-blind, treat-to-target trial. It evaluated the efficacy and safety of Fiasp ® compared with conventional insulin aspart, both with insulin degludec, with or without metformin, in adults with advanced type 2 diabetes (living with type 2 diabetes for 10 years or more), with HbA1c levels ranging from 7% to 10%, and who have been treated with a basal-bolus insulin regimen for at least one year.    

The findings showed that Fiasp ® was non-inferior in change from baseline in HbA1c (overall blood sugar) after 16 weeks versus conventional insulin aspart (estimated treatment difference [ETD] -0.04%). Fiasp ® was superior to conventional insulin aspart in one-hour post-meal blood sugar increment (ETD -0.40 mmol/L). The overall rate of treatment-emergent severe or blood sugar-confirmed hypoglycaemia was also statistically significantly lower for Fiasp ® compared with conventional insulin aspart.

About Fiasp ®

Fiasp ® is the only approved, new-generation, ultra-fast acting2-4 mealtime insulin injection. Fiasp ® is insulin aspart in an innovative formulation, in which two excipients have been added5: Vitamin B3 (niacinamide) increases the speed of absorption6, and a naturally occurring amino acid (L-arginine) for stability, when compared with the conventional formulation of insulin aspart.5 The result is a mealtime insulin that more closely mimics the natural physiological insulin response of a person without diabetes after a meal, compared with conventional insulin aspart.5

Fiasp ® is indicated for the treatment of diabetes in adults, adolescents and children aged one  year and above.7

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.


  1. Lane W, et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes.  Poster presentation at the 55th Annual Meeting of EASD. 16-20 September 2019; Barcelona, Spain.
  2. Cengiz E, et al. Moving toward the ideal insulin for insulin pumps. Expert Review of Medical Devices 2016; 13(1):57-69.
  3. Heinemann L and Muchmore DB. Ultrafast-acting insulins: state of the art. Journal of Diabetes Science and Technology 2012; 6:728-42.
  4. Russell-Jones D, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017; 40(7):943-50.
  5. Heise T, et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clinical Pharmacokinetics 2017; 56(5):551-9.
  6. Kildegaard J, et al. Elucidating the mechanism of absorption of fast-acting insulin aspart: the role of niacinamide. Pharmaceutical Research 2019; 11;36(3):49.
  7. Fiasp ® EMA Summary of Product Characteristics. Bagsværd, Denmark: Novo Nordisk A/S. Last updated: July 2019.

Logo - https://mma.prnewswire.com/media/482186/Novo_Nordisk_Logo.jpg

Further information


Mette Kruse Danielsen

+45 3079 3883



Peter Hugreffe Ankersen

+45 3075 9085


Valdemar Borum Svarrer

+45 3079 0301


Ann Søndermølle Rendbæk

+45 3075 2253



More News by PR Newswire India

Shanghai International Money Fair - one of China's largest financial fairs will be held in December

Europe's Most Trusted Crypto And Precious Metal Companies Partner To Create Gold Token Secured By Bitcoin Network

RGE Commits US$200 Million to Next-Generation Textile Fibre Innovation and Technology

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

INSIDE INFORMATION: BW LPG Contemplated Sale of Shares

School House Crafts Multi-Sensory Journey of Discovery and Re-collection for La Mer Campaign Exhibition

Vevue Partners with CBX Exchange for Initial Auction Offering

Frost & Sullivan Recognizes Pepco Holdings and Carlsbad Municipal Water District with Excellence in Resourcefulness Awards at Itron Utility Week

His Holiness The Dalai Lama Awarded Honorary Doctorate by Chitkara University

Surplus Keslow Cinematography Gear Up For Auction

Libyan Investment Authority Loses Claim in the UK Court of Appeal - London

Artificial Intelligence for Risk Management Process by MovingNow

Maruti Suzuki Arena Devils Circuit Season 2019-20 Draws Over 6K Runners in Hyderabad

Quectel Achieves Industry's First 5G Data Call over 5G mmWave Module

Artprice by Artmarket: The Gagosian's Grand Projects for the Late Simon HantaĂŻ (1922-2008)

Ryan International Group of Schools Receive India's Most Respected Brand Award 2019

JD Institute Of Fashion Technology, South Announced its New Domain

VeChain Is Leading Co-sponsor of GDST Seafood Trackathons

The World's Largest Automakers, Along with MOBI, Announce a Joint Proof of Concept for the First Vehicle Identity on Blockchain

Indiannica Learning Announces the Launch of Indiannica Quiz League

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

Telangana: Three members appointed to Te...
SC seeks status report on stubble burnin...
US Navy submarine support ship arrives i...
UP govt suspends Maharajganj DM, five ot...
Delhi cabinet nod for new skill, entrepr...
Ex-chief engineer arrested in Tripura PW...
 Top Stories
Maha polls: Rahul to hold two publi... 
Miranda Lambert posts adorable birt... 
Heavy rain predicted in Kerala, Kar... 
Devastating fire breaks out at plas... 
Zoe Kravitz roped in to play Catwom... 
Turkish troops advance towards Manb... 
CA to match prize money for women's... 
Phil Simmons appointed the head coa...